NICE backs ibrutinib regimen for untreated mantle cell lymphoma

RegulatoryapprovedibrutinibPositive

AI Analysis

Summary

NICE has issued guidance supporting ibrutinib as a first-line treatment regimen for untreated mantle cell lymphoma, providing an alternative to transplant-based therapies. This represents a significant regulatory endorsement for the drug's use in this indication.

Outcome Details

NICE guidance backs ibrutinib regimen for untreated mantle cell lymphoma as first-line alternative to transplant-based care

Importance:6/10

Sentiment:

0.70

mantle cell lymphomaibrutinibNICE guidancefirst-line therapyregulatory approval

Related Companies

$TRAX

Read the original article

Published by PharmaTimes on September 10, 2026 10:31 AM

Read Original